Outlook Therapeutics News

Express News | Outlook Therapeutics Submits Marketing Authorization Application For ONS-5010 In Wet AMD To MHRA

BenzingaMay 13 08:51 ET

Express News | Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (Maa) for Ons-5010 as a Treatment for Wet AMD

ReutersMay 13 08:50 ET

Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment

GlobeNewswireMay 9 08:45 ET

Express News | Outlook Therapeutics To Present At Retina World Congress 2024

BenzingaMay 2 09:12 ET

Outlook Therapeutics to Present at the Retina World Congress 2024

ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment

GlobeNewswireMay 2 09:05 ET

Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevaciz

GlobeNewswireApr 29 09:00 ET

Outlook Therapeutics Files to Sell 2.78M Shares of Common Stock for Holders

Seeking AlphaApr 26 16:40 ET

Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors -- Barrons.com

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen

Barron'sApr 26 06:37 ET

Express News | Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

Moomoo 24/7Apr 15 16:15 ET

Express News | Outlook Therapeutics Files Prospectus Supplement Related To Offer, Sale Of Up To $93.7M Of Common Stock That May Be Sold Under Sales Agreement

Moomoo 24/7Apr 12 16:33 ET

Express News | Outlook Therapeutics - Files Prospectus Supplement Related to Offer, Sale of up to $93.7 Mln of Common Stock That May Be Sold Under Sales Agreement

Moomoo 24/7Apr 12 16:30 ET

Insiders Are Piling Into These 10 Healthcare Stocks in 2024

Yahoo FinanceApr 10 15:30 ET

Insiders Buying Outlook Therapeutics And 2 Other Stocks

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the st

BenzingaApr 1 10:46 ET

Outlook Therapeutics(OTLK.US) Director Buys US$22,241.83 in Common Stock

$Outlook Therapeutics(OTLK.US)$ Director Haddadin Yezan Munther purchased 1,881.71 shares of Common Stock on Mar 28, 2024 at an average price of $11.82 for a total value of $22,241.83.Source: Announce

moomoo NewsMar 29 11:20 ET

Outlook Therapeutics Files for $300M Mixed Securities Shelf

Seeking AlphaMar 28 17:15 ET

Express News | Tang Capital Partners Discloses 9.99% Passive Stake In Outlook Therapeutics

Moomoo 24/7Mar 28 16:16 ET

Express News | Outlook Therapeutics Shares Are Trading Higher After BTIG Upgraded the Stock From Neutral to Buy and Announced a $50 Price Target

Moomoo 24/7Mar 27 13:22 ET

Outlook Therapeutics Raised to Buy From Neutral by BTIG

Outlook Therapeutics Raised to Buy From Neutral by BTIG

Dow JonesMar 27 07:27 ET

Express News | BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target

Moomoo 24/7Mar 27 07:19 ET

Buy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Target

TipRanksMar 27 06:45 ET